MONTVALE, N.J., Oct. 1, 2008 (GLOBE NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electroceutical(r) therapy systems designed to target and enhance the body's anti-inflammatory and angiogenic responses, today announced that on September 29, 2008 the Company received a deficiency notice from The Nasdaq Stock Market notifying the Company that it is not in compliance with Nasdaq Marketplace Rule 4310(c)(4) because the Company's common stock closed below the minimum bid price of $1.00 per share for the last 30 consecutive business days.
